Contract research news in brief
pharmafile | February 2, 2010 | News story | Research and Development |Â Â CRO, PRA, QuintilesÂ
Our round-up of contract research news includes alliances for Quintiles and PRA International, a new CRO serving the Eastern European market and Medpace’s acquisition of a German regulatory services company.
Contract services organisation Quintiles has formed a strategic alliance with Belgian drug developer Movetis in which it will support the UK and German launch of the firm’s new chronic constipation therapy Resolor (prucalopridein). In addition to a contract sales agreement, the alliance covers areas such as market intelligence and analytics, regulatory and post-marketing pharmacovigilance. The agreement is likely to be extended later this year to cover other European markets.
PRA International has improved its ability to carry out cancer studies in Latin America via a partnership with Brazilian counterpart Oncopartners and IBC, a non-profit oncology research network that includes Brazil’s largest cancer hospitals. The network treats around 140,000 cancer patients each year. The move ties in with a trend among CROs to expand their clinical research networks into emerging markets in order to overcome patient recruitment difficulties in mature markets such as Western Europe and North America.
A new CRO – EastHORN Clinical Services – has officially started operations after the final integration of its operational units located throughout the majority of countries in Central and East Europe (CEE). The company was formerly known as Unimed and was founded in 2004. It offers phase I to IV trial services and for early-stage studies has formed a collaboration with a hospital in Prague, Czech Republic.
US drug development services company Medpace has acquired Medical Consulting Dr. Schlichtiger, a Munich, Germany-based CRO that provides regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies. The deal gives Medpace a hub in central Europe for regulatory submissions and approvals as well as drug safety management and reporting. The integration of the Germany company is due for completion in mid-2010.
CRO and eClinical technology specialist Clinipace Worldwide has appointed Bud Owen as its chief financial officer, while Daryl Porter has joined the company as chief technology officer with responsibility for the firm’s service engineering, product engineering, and cloud computing infrastructure teams.
Agilux Laboratories has launched a new suite of liquid chromatography-mass spectrometry (LC/MS/MS) bioanalytical services for clients’ non-clinical and clinical studies. Agilux specialises in bioanalytical and in vitro ADMET (absorption, distribution, metabolism, excretion and toxicology) services for the biopharmaceutical and has built a new unit to provide the new services at its facility in Massachusetts, USA.
PharmaNet Development Group has named Dr Steven Leventer to the position of vice president, clinical research – neuroscience. Leventer joins PharmaNet from Wyeth (now part of Pfizer) and was formerly vice president for central nervous system development at Quintiles.
Related Content
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
From molecule to market and beyond: Uniphar announces extended global commercialization platform
22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service …
Quintiles to merge with IMS Health
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement …
